Potentiation of Muscarinic M

Allosteric Regulation / drug effects Allosteric Site / drug effects Amino Acid Sequence Animals CHO Cells Cricetulus Dose-Response Relationship, Drug Female Humans Male Muscarinic Agonists / chemistry Organ Culture Techniques Receptor, Muscarinic M3 / agonists Urinary Bladder / drug effects

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
10 2021
Historique:
received: 03 05 2021
accepted: 06 07 2021
pubmed: 11 7 2021
medline: 31 12 2021
entrez: 10 7 2021
Statut: ppublish

Résumé

Muscarinic M

Identifiants

DOI: 10.1124/jpet.121.000709 PMID: 34244231
pubmed: 34244231
pii: jpet.121.000709
doi: 10.1124/jpet.121.000709
doi:

Substances chimiques

Muscarinic Agonists 0
Receptor, Muscarinic M3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-73

Informations de copyright

Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Risa Okimoto (R)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.) risa.okimoto@astellas.com.

Katsutoshi Ino (K)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Kenichiro Ishizu (K)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Hajime Takamatsu (H)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Kazuyuki Sakamoto (K)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Hironori Yuyama (H)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Hideyoshi Fuji (H)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Akiyoshi Someya (A)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Akiyoshi Ohtake (A)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Takao Ishigami (T)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Noriyuki Masuda (N)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Masahiro Takeda (M)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Shunichi Kajioka (S)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Naoki Yoshimura (N)

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (R.O., K.In., K.Is., H.T., K.S., H.Y., H.F., A.S., A.O., T.I., N.M., M.T.); Department of Pharmaceutical Sciences, International University of Health and Welfare, Fukuoka, Japan (S.K.); and Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (N.Y.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Régulation allostérique › Potentiation of Muscarinic M
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › Site allostérique › Potentiation of Muscarinic M
questionsmedicales.fr › Sciences de l'information › Sources d'information › Services d'information › Documentation › Données de séquences moléculaires › Séquence d'acides aminés › Potentiation of Muscarinic M
questionsmedicales.fr › Eucaryotes › Animaux › Potentiation of Muscarinic M
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules CHO › Potentiation of Muscarinic M
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Arvicolinae › Cricetinae › Cricetulus › Potentiation of Muscarinic M
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Potentiation of Muscarinic M
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Potentiation of Muscarinic M
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents cholinergiques › Agonistes cholinergiques › Agonistes muscariniques › Potentiation of Muscarinic M
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture d'organes › Potentiation of Muscarinic M
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs cholinergiques › Récepteur muscarinique › Récepteur muscarinique de type M3 › Potentiation of Muscarinic M
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Vessie urinaire › Potentiation of Muscarinic M